logo
logo
CYRX stock ticker logo

Cryoport, Inc.

NASDAQ•CYRX
CEO: Mr. Jerrell W. Shelton
Sector: Industrials
Industry: Integrated Freight & Logistics
Listing Date: 2005-08-22
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.
Contact Information
112 Westwood Place, Suite 350, Brentwood, TN, 37027, United States
949-470-2300
www.cryoportinc.com
Market Cap
$405.06M
P/E (TTM)
5.4
35.3
Dividend Yield
--
52W High
$11.45
52W Low
$4.63
52W Range
51%
Rank63Top 94.0%
1.8
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$45.45M+0.00%
4-Quarter Trend

EPS

-$0.27+0.00%
4-Quarter Trend

FCF

-$15.73M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Total Revenue Growth Total revenue reached $176.2M, marking a 12.4% increase. Life Sciences Services revenue grew 17.6% to $96.5M.
Profitability Reversal Achieved Net Income of $78.3M in 2025, a significant shift from Net Loss of ($114.8M) reported in 2024.
Strategic Divestiture Gain Completed CRYOPDP divestiture for $133.0M in Q2 2025, resulting in a $117.0M gain recognized in operations.
CGT Market Support Supported 760 clinical trials globally; 20 commercial therapies generated $33.4M revenue, increasing 28.6%.

Risk Factors

Component Supply Dependency Dependence on third-party component availability; delays or increased procurement costs could adversely affect financial performance.
Global Regulatory Exposure Operations face risks from changing international trade policies, currency fluctuations, and complex governmental regulations.
Product Liability Exposure Risk of liability claims exceeding insurance coverage, particularly concerning products used in human reproductive medicine.
Cybersecurity System Failure Critical information systems face constant cyberattacks; system compromise could materially harm operations and reputation.

Outlook

Digital Strategy Enhancement Established Enterprise Technology Group (ETG) to drive digital initiatives, integrating AI and advanced analytics across platforms.
Infrastructure Expansion Plans Opened Paris Global Supply Chain Center in 2025; planning another center in Santa Ana, California, late 2026.
MVE System Connectivity Plans to introduce MVE CryoVerse Ecosystem in 2026 for real-time monitoring and enhanced compliance visibility.
Future Capital Requirements Management recognizes potential need for additional equity or debt capital until sustained profitability is achieved.

Peer Comparison

Revenue (TTM)

FWRD stock ticker logoFWRD
$2.50B
+0.8%
CODI stock ticker logoCODI
$1.87B
-4.8%
TWI stock ticker logoTWI
$1.83B
-0.9%

Gross Margin (Latest Quarter)

ZIP stock ticker logoZIP
89.1%
-0.3pp
BYRN stock ticker logoBYRN
59.8%
-2.3pp
FWRD stock ticker logoFWRD
48.4%
-14.5pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
FWRD$688.40M-6.3-77.1%91.5%
SWBI$633.59M52.73.3%20.2%
EBF$542.33M12.914.1%2.9%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
3.5%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
25%
Cash Flow Needs Attention

Deep Research

Next earnings:Apr 30, 2026
|
EPS:-$0.22
|
Revenue:$44.87M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data